IMNN vs. PLUR, CARM, CALC, RPHM, RMTI, ANEB, BLRX, KZR, EQ, and EGRX
Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Pluri (PLUR), Carisma Therapeutics (CARM), CalciMedica (CALC), Reneo Pharmaceuticals (RPHM), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), BioLineRx (BLRX), Kezar Life Sciences (KZR), Equillium (EQ), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "medical" sector.
Pluri (NASDAQ:PLUR) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
16.6% of Pluri shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 10.2% of Pluri shares are owned by company insiders. Comparatively, 5.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pluri has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Imunon has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Imunon has a net margin of 0.00% compared to Imunon's net margin of -6,339.59%. Pluri's return on equity of -122.68% beat Imunon's return on equity.
Imunon received 9 more outperform votes than Pluri when rated by MarketBeat users.
In the previous week, Pluri had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Imunon. Pluri's average media sentiment score of 1.88 beat Imunon's score of 1.87 indicating that Imunon is being referred to more favorably in the news media.
Imunon has a consensus price target of $12.00, indicating a potential upside of 727.59%. Given Pluri's higher possible upside, analysts clearly believe Imunon is more favorable than Pluri.
Summary
Imunon beats Pluri on 11 of the 16 factors compared between the two stocks.
Get Imunon News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
